Food Supplement Effect on Overweight or Moderate Obesity (PHYTOENIX)
Effect of Carrot Seed and Rose Hip Extracts on Weight Management in Subjects With Overweight or Moderate Obesity. A Controlled, Randomized and Double-blind Study.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Paris, França, 75013
- Institute of Cardiometabolism And Nutrition
-
-
Nord
-
Lille, Nord, França, 59019
- NutrInvest - Institut Pasteur de Lille
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- BMI between 25 and 35 kg / m² (limits excluded),
- Having a fat mass (measured by impedance balance in kg) according to the following table:
Men 18-29 years : ≥ 21.2 kg; Men 30-49 years : ≥ 21.6 kg; Men 50-65 years : ≥ 23.8 kg; Women 18-29 years : ≥ 31.4 kg; Women30-49 years : ≥ 31.8 kg; Women 50-65 years : ≥ 33.9 kg.
- Willing to observe dietetic plan in accordance with dietitian evaluation,
- Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,
- Affiliated with a social security scheme.
Exclusion Criteria:
Dyslipidemia or hyperlipidemia:
- Fasting total cholesterol ≥ 3.0 g / L
- Fasting triglycerides> 2.5 g / L
- with heterozygous familial hypercholesterolemia,
- Diabetes treated or not with medication,
- With severe hepatic and / or renal impairment, liver enzyme level (ALT and / or AST) greater than 2.5 times the upper normal limit,
- TSH abnormal or not stable for at least 3 months,
- History of cardiac disease (heart attack, stroke, coronary artery disease) or chronic inflammatory disease in the previous 6 months,
- With cancer or having had cancer in the 3 years preceding the study, with the exception of basal cell cancers of the skin,
- Taking drugs known to have an impact on weight management (corticosteroids, neuroleptics, anti-HIV triple therapy, etc.) in the month preceding inclusion and / or likely to consume them during the test,
- Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study,
- Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression,
- Weight loss treatment in the previous 6 months or having followed a specific treatment promoting weight loss,
- Non stable weight during the last 6 months (>5% change in total weight),
- With metal implant (to allow DEXA measurement),
- Blood donation in the month before the start of the study and during the study,
- Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and / or likely to take during the test,
- Following or having followed a hypocaloric diet (energy intake <1,500 kCal / day) in the month preceding inclusion and / or likely to undertake this diet during the test,
- Following a particular diet (vegan),
- Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting),
- Intense sport exercise practice (physical activity more than 4 hours per week) or not willing to maintain their exercise practises stable during the test,
- Smoking more than 5 cigarettes per day, unstable cigarettes consumption, or smoking cessation during 6 months preceding the inclusion or during the test,
- Bariatric surgery or who has a gastroplasty ring,
- Consuming more than 2 (women) or 3 (men) standard drinks of alcoholic beverage daily,
- Consuming illicit drugs,
- Using topical anti-cellulite treatments,
- For woman: Pregnant or planned to become, breastfeeding, with non-effective contraception,
- Known allergy to one of the component of the supplement (carrot and rose hip),
- Suffering from serious illnesses such as cancer, recent myocardial infarction, serious digestive pathologies or others diseases found to be inconsistent with the conduct of the study by the investigator,
- Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
- Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
- Presenting a psychological or linguistic incapability to sign the informed consent,
- Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: High dose
4 capsules with 1.6g of active product per day: 2 at breakfast and 2 at dinner
|
Food supplements are consumed during 3 months by healthy volunteers.
|
|
Comparador Ativo: Low dose
4 capsules with 0.8g of active product per day: 2 at breakfast and 2 at dinner
|
Food supplements are consumed during 3 months by healthy volunteers.
|
|
Comparador de Placebo: Maltodextrin
4 placebo capsules (maltodextrin) per day: 2 at breakfast and 2 at dinner
|
Food supplements are consumed during 3 months by healthy volunteers.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline weight at 3 months
Prazo: 0 month (inclusion), 3 months
|
Weight (unit: kg)
|
0 month (inclusion), 3 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body mass composition by DEXA (dual energy x-ray absorptiometry)
Prazo: 0 month (inclusion), 3 months
|
Lean body mass, total fat mass, subcutaneous fat mass, visceral fat mass (unit: g)
|
0 month (inclusion), 3 months
|
|
Anthropometric parameters
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Hip circumference, waist circumference and thigh circumference (unit: cm)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Fasting glycemia
Prazo: 0 month (inclusion), 3 months
|
Carbohydrate metabolism: Fasting glycemia (unit: g/l)
|
0 month (inclusion), 3 months
|
|
Insulinemia
Prazo: 0 month (inclusion), 3 months
|
Carbohydrate metabolism: Insulinemia (unit: mU/l)
|
0 month (inclusion), 3 months
|
|
HbA1c
Prazo: 0 month (inclusion), 3 months
|
Carbohydrate metabolism: HbA1c (unit: percent)
|
0 month (inclusion), 3 months
|
|
HOMA index
Prazo: 0 month (inclusion), 3 months
|
Carbohydrate metabolism: determination of the HOMA index (calculated)
|
0 month (inclusion), 3 months
|
|
Lipid metabolism
Prazo: 0 month (inclusion), 3 months
|
Total cholesterol, HDL, LDL, Triglycerides (unit: g/l)
|
0 month (inclusion), 3 months
|
|
Free fatty acids
Prazo: 0 month (inclusion), 3 months
|
Lipid metabolism: free fatty acids (unit: micromol/l)
|
0 month (inclusion), 3 months
|
|
Hepatic metabolism
Prazo: 0 month (inclusion), 3 months
|
Creatinine (unit: mg/l)
|
0 month (inclusion), 3 months
|
|
Transaminases
Prazo: 0 month (inclusion), 3 months
|
Hepatic metabolism: ASAT/ALAT (unit: UI/l)
|
0 month (inclusion), 3 months
|
|
Sedimentation rate
Prazo: 0 month (inclusion), 3 months
|
Blood parameters: Sedimentation rate (unit: mm)
|
0 month (inclusion), 3 months
|
|
Blood count
Prazo: 0 month (inclusion), 3 months
|
Blood parameters: Blood count (unit: G/L)
|
0 month (inclusion), 3 months
|
|
Thyroid Stimulating Hormone
Prazo: 0 month (inclusion), 3 months
|
TSH (Thyroid Stimulating Hormone) (unit: mUI/l)
|
0 month (inclusion), 3 months
|
|
High sensible C-reactive protein
Prazo: 0 month (inclusion), 3 months
|
CRPhs (high sensible C-reactive protein) (unit: mg/l)
|
0 month (inclusion), 3 months
|
|
Heart rate
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Hemodynamic parameters: Heart rate (unit: Pul/min)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Blood pressure
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Hemodynamic parameters: Systolic blood pressure (unit: mm Hg) and Diastolic blood pressure (unit: mm Hg)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Body mass composition by impedancemetry
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Lean body mass and total fat mass (unit: percent)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Weight
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Anthropometric parameters: weight (unit: kg)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Height
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Anthropometric parameters: height (unit: cm)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
|
Body Mass Index
Prazo: 0 month (inclusion), 1 month, 2 months, 3 months
|
Anthropometric parameters: determined Body Mass Index (unit: kg/m²)
|
0 month (inclusion), 1 month, 2 months, 3 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2021-A02422-39
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .